BioCryst Pharmaceuticals Inc (BCRX) stock
BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.61−0.07 (-0.91%)
Close on Nov 13, 2026Market cap $1.94BP/E –Yield –
BioCryst Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
BioCryst Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2026 was -30.1%. For fiscal 2025 it was 39.0%, against -0.6% the year before. The highest annual figure on record is 39.0% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 39.0% | +39.5 |
| FY2024 | Dec 31, 2024 | -0.6% | +30.7 |
| FY2023 | Dec 31, 2023 | -31.3% | +23.5 |
| FY2022 | Dec 31, 2022 | -54.8% | +58.3 |
| FY2021 | Dec 31, 2021 | -113.1% | +868.0 |
| FY2020 | Dec 31, 2020 | -981.1% | −777.5 |
| FY2019 | Dec 31, 2019 | -203.7% | +252.5 |
| FY2018 | Dec 31, 2018 | -456.2% | −228.3 |
| FY2017 | Dec 31, 2017 | -227.9% | −43.5 |
| FY2016 | Dec 31, 2016 | -184.4% | −102.7 |
| FY2015 | Dec 31, 2015 | -81.7% | +254.6 |
| FY2014 | Dec 31, 2014 | -336.4% | −159.1 |
| FY2013 | Dec 31, 2013 | -177.2% | −48.4 |
| FY2012 | Dec 31, 2012 | -128.9% | +123.6 |
| FY2011 | Dec 31, 2011 | -252.4% | −197.4 |
| FY2010 | Dec 31, 2010 | -55.1% | −36.7 |
| FY2009 | Dec 31, 2009 | -18.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 29.6% | +11.0 |
| Q2 FY2026 | Jun 30, 2026 | 45.1% | +26.9 |
| Q1 FY2026 | Mar 31, 2026 | -448.6% | −463.1 |
| Q4 FY2025 | Dec 31, 2025 | 64.0% | +67.5 |
| Q3 FY2025 | Sep 30, 2025 | 18.6% | +12.0 |
| Q2 FY2025 | Jun 30, 2025 | 18.2% | +10.2 |
| Q1 FY2025 | Mar 31, 2025 | 14.6% | +30.2 |
| Q4 FY2024 | Dec 31, 2024 | -3.4% | +42.3 |
| Q3 FY2024 | Sep 30, 2024 | 6.6% | +20.3 |
| Q2 FY2024 | Jun 30, 2024 | 8.0% | +33.1 |
| Q1 FY2024 | Mar 31, 2024 | -15.6% | +25.7 |
| Q4 FY2023 | Dec 31, 2023 | -45.7% | +12.5 |
| Q3 FY2023 | Sep 30, 2023 | -13.7% | +9.3 |
| Q2 FY2023 | Jun 30, 2023 | -25.1% | +27.9 |
| Q1 FY2023 | Mar 31, 2023 | -41.3% | +58.8 |
| Q4 FY2022 | Dec 31, 2022 | -58.2% | +52.4 |
| Q3 FY2022 | Sep 30, 2022 | -23.0% | +85.8 |
| Q2 FY2022 | Jun 30, 2022 | -53.0% | +6.2 |
| Q1 FY2022 | Mar 31, 2022 | -100.1% | +169.5 |
| Q4 FY2021 | Dec 31, 2021 | -110.6% | +1194.3 |
| Q3 FY2021 | Sep 30, 2021 | -108.8% | +593.7 |
| Q2 FY2021 | Jun 30, 2021 | -59.2% | +1282.1 |
| Q1 FY2021 | Mar 31, 2021 | -269.6% | +580.1 |
| Q4 FY2020 | Dec 31, 2020 | -1304.9% | −1304.6 |
| Q3 FY2020 | Sep 30, 2020 | -702.5% | +1274.9 |
| Q2 FY2020 | Jun 30, 2020 | -1341.3% | +1070.1 |
| Q1 FY2020 | Mar 31, 2020 | -849.6% | −351.4 |
| Q4 FY2019 | Dec 31, 2019 | -0.3% | +925.4 |
| Q3 FY2019 | Sep 30, 2019 | -1977.4% | −17.7 |
| Q2 FY2019 | Jun 30, 2019 | -2411.5% | −2265.4 |
| Q1 FY2019 | Mar 31, 2019 | -498.2% | +60.5 |
| Q4 FY2018 | Dec 31, 2018 | -925.7% | −466.5 |
| Q3 FY2018 | Sep 30, 2018 | -1959.6% | −1807.2 |
| Q2 FY2018 | Jun 30, 2018 | -146.1% | +354.6 |
| Q1 FY2018 | Mar 31, 2018 | -558.7% | −445.5 |
| Q4 FY2017 | Dec 31, 2017 | -459.2% | −368.0 |
| Q3 FY2017 | Sep 30, 2017 | -152.4% | – |
| Q2 FY2017 | Jun 30, 2017 | -500.7% | – |
| Q1 FY2017 | Mar 31, 2017 | -113.2% | – |
| Q4 FY2016 | Dec 31, 2016 | -91.1% | – |
See a number that looks wrong?